Rigel Pharmaceuticals, Inc. (RIGL)
| Market Cap | 564.75M |
| Revenue (ttm) | 294.28M |
| Net Income (ttm) | 367.02M |
| Shares Out | 18.48M |
| EPS (ttm) | 19.48 |
| PE Ratio | 1.57 |
| Forward PE | 7.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 309,407 |
| Open | 30.69 |
| Previous Close | 30.51 |
| Day's Range | 30.47 - 31.35 |
| 52-Week Range | 16.88 - 52.24 |
| Beta | 1.27 |
| Analysts | Strong Buy |
| Price Target | 45.67 (+49.44%) |
| Earnings Date | May 5, 2026 |
About RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test;... [Read more]
Financial Performance
In 2025, Rigel Pharmaceuticals's revenue was $294.28 million, an increase of 64.15% compared to the previous year's $179.28 million. Earnings were $367.02 million, an increase of 1999.08%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for RIGL stock is "Strong Buy." The 12-month stock price target is $45.67, which is an increase of 49.44% from the latest price.
News
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market close o...
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. I...
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET fusion-positive NSCLC SOUTH SAN FRANCISCO, Calif...
Rigel Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 sales and net income were driven by strong demand, portfolio expansion, and a one-time tax benefit. Continued double-digit growth is expected in 2026, with a focus on advancing R289 and disciplined capital allocation.
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million 2025 total revenues of approximately $294.3...
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results after ...
Rigel Appoints Michael P. Miller to the Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P.
Rigel Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted robust commercial growth, a strong financial turnaround, and a promising pipeline led by R289 for low-risk MDS. Strategic expansion, disciplined financial management, and late-stage in-licensing are set to drive further growth through 2030.
Rigel Provides Business Update and 2026 Outlook
Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million and contract revenues of $4.4 million In the dose escalation phase of the Pha...
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announ...
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33% (6/18) of ...
Rigel Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
Significant year-over-year sales growth was achieved across key hematology and oncology products, with expanded global partnerships and a robust late-stage pipeline. Clinical progress in IRAK1/4 and olutasidenib, along with strong financials and increased revenue guidance, position the business for continued expansion.
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today anno...
Rigel Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
Strong commercial growth driven by three expanding products and disciplined financial management has enabled robust profitability and cash generation. Pipeline progress is highlighted by R289 for low-risk MDS and multiple collaborations, with a focus on in-licensing synergistic assets and expanding into new indications.
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously treated with venetoclax-based regimen...
Rigel to Present at the Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today anno...
Rigel Pharmaceuticals Earnings Call Transcript: Q3 2025
Record Q3 2025 revenue and net income driven by strong commercial execution and product demand, with raised full-year guidance reflecting 55%-59% anticipated growth. Pipeline progress includes R289 and olutasidenib, with strategic collaborations and international expansion ongoing.
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million Generated $27.9 million ...
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
Oral presentation to feature updated data from the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS Four poster presentati...
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'
Rigel Pharmaceuticals has landed on CNBC's list of top performing stocks of companies located in San Francisco.
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close o...
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS SOUTH SAN FRANCISCO, Calif. , Oct. 8, 2025 /PRNewswire/ -- Rigel Pha...
Rigel Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The conference highlighted robust growth in hematology and oncology, with strong commercial performance from TAVALISSE, REZLIDHIA, and GAVRETO, and a promising pipeline led by the IRAK1/4 inhibitor. Financials showed significant revenue and income growth, with raised guidance for 2025.
Rigel Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025
Strong commercial growth was driven by three key products, with expanded use and updated guidelines fueling adoption. Promising pipeline progress includes R289 in lower-risk MDS and olutasidenib in glioma, while profitability and cash generation support increased guidance and future investments.
Rigel to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today anno...